Fibrosis improvement in patients with HCV treated with direct-acting antivirals
European Journal of Gastroenterology & Hepatology — McPhail J, Sims OT, Guo Y, et al. | June 24, 2021
In the present study, the researchers sought to evaluate changes in elastography scores from baseline to 1-year follow-up in hepatitis C virus (HCV) patients, identify factors that were independently correlated with improvement in fibrosis staging in patients who received treatment, as well as identify factors that were independently related to no improvement in fibrosis staging among patients who achieved sustained virologic responses (SVR). Patients who received HCV treatment and those who did not receive treatment (n = 240) had ultrasound elastography and laboratory tests performed and collected at baseline and at a 1-year follow-up. Higher pre-treatment fibrosis stages were positively linked to improvement in fibrosis staging at 1-year follow-up in multivariate analysis of patients who received treatment. Higher BMI was negatively related to improvement in fibrosis staging. This study adds to the growing body of evidence that fibrosis regression is possible in a significant proportion of patients who achieve SVR with all-oral DAA regimens. Importantly, fibrosis regression is more likely in patients with advanced stages of fibrosis and less likely in obese patients.